Another Indiana Senate panel has unanimously approved a bill that would fund clinical research trials into psilocybin.
The Senate Appropriations Committee adopted a technical amendment before sending the legislation to the floor in a 14-0 vote. The action follows the psychedelics proposal being passed, also unanimously, by the Senate Health and Provider Services Committee last month.
“Psilocybin has been given breakthrough therapy by the FDA and it’s not a fringe service…anymore,” Sen. Ed Charbonneau (R), the bill’s sponsor, said ahead of Thursday’s latest vote.
“Research institutes would be able to apply for the funds to conduct studies to evaluate efficacy of psilocybin as an alternative treatment for PTSD and combat veterans and first responders with anxiety, depression, bipolar disorder, chronic pain and migraines,” he said. “It’s something that’s out there that is providing hope for for individuals who suffer with these issues. And right now there isn’t a lot of hope for them, and I look at psilocybin is a good thing.”
If it becomes law, the measure would create a therapeutic psilocybin research fund “for the purpose of providing financial assistance to research institutions in Indiana to study…the use of psilocybin to treat mental health and other medical conditions.”
Read full article on Marijuana Moment
